Obstructive sleep apnea (OSA) affects an estimated 936 million adults globally yet remains undiagnosed in up to 80% of cases. The STOP-BANG questionnaire is a validated 8-item tool that takes under two minutes to complete and identifies patients at risk for moderate-to-severe OSA — enabling timely referral for formal sleep testing.
Why OSA Screening Matters
Untreated OSA causes repeated oxygen desaturations and sleep fragmentation, stressing the cardiovascular and metabolic systems. The consequences include a 2–4× increased risk of hypertension, a 3× risk of atrial fibrillation, a 2× risk of type 2 diabetes, and significant impairment of cognitive function and daytime alertness. Patients with undiagnosed OSA face a meaningfully elevated risk of motor vehicle accidents. In the perioperative setting, unrecognised OSA is associated with postoperative respiratory failure, longer ICU stays, and higher 30-day mortality.
How STOP-BANG Was Developed
Chung et al. (2008) derived and validated STOP-BANG in a cohort of 2,467 surgical patients at the Toronto Western Hospital. The tool was designed to balance simplicity (binary Yes/No answers, no measurements required) with sensitivity sufficient for preoperative screening. At a threshold of 3 or more, sensitivity for moderate-to-severe OSA (AHI ≥ 15) was 93% and for severe OSA (AHI ≥ 30) was 100%. Subsequent meta-analyses across primary care, bariatric, and general population settings have confirmed its validity across different demographic groups.
The combined high-risk pathway — scoring High Risk for a total score of only 3–4 when STOP ≥ 2 and at least one of Male / BMI>35 / Neck>16" is present — was formalised by Nagappa et al. (2015) to improve specificity. This refinement reduces unnecessary referrals while maintaining the high sensitivity needed to avoid missing true moderate-to-severe cases.
Limitations and Who Should Be Referred
STOP-BANG is a screening tool, not a diagnostic one. A high score does not confirm OSA; it identifies people who need a formal sleep study. A low score substantially reduces the probability of significant OSA but does not exclude it entirely — the tool is optimised for sensitivity, not specificity. It performs less well in women (who tend to present with atypical symptoms), patients under 30, and those with central sleep apnea, which is a distinct physiological mechanism not captured by the questionnaire's items.
Any patient with a score of 3 or more who is scheduled for elective surgery, who has unexplained cardiovascular risk factors, or whose daytime function is impaired by sleepiness should discuss results with their physician. Definitive diagnosis requires polysomnography (PSG) or a validated home sleep apnea test (HSAT) interpreted by a board-certified sleep medicine specialist.